Filing Flows › Comparisons › SRZN vs ALLO
Surrozen vs Allogene Therapeutics: SRZN and ALLO compared
Surrozen is the larger company: $5.0M of revenue in its latest quarter (Q2 2026) against $4.6M for Allogene Therapeutics (Q2 2026).
Where the money goes: SRZN and ALLO
Surrozen (SRZN) · Q2 2026
Surrozen, Q2 2026: revenue $5.0M (+409% year over year), operating margin -207.4%, net earnings $50.2M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
Allogene Therapeutics (ALLO) · Q2 2026
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
| Surrozen (SRZN) | Allogene Therapeutics (ALLO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $5.0M | $4.6M |
| Revenue growth, Y/Y | +409% | — |
| Operating margin | -207.4% | n/m |
| Net earnings | $50.2M | −$42.7M |
| Net margin | — | -919.8% |
| Operating cash flow | −$7.4M | −$32.0M |
Questions
Which is bigger, Surrozen or Allogene Therapeutics?
Surrozen is the larger company: $5.0M of revenue in its latest quarter (Q2 2026) against $4.6M for Allogene Therapeutics (Q2 2026).
More: Surrozen earnings · how Surrozen makes money · Allogene Therapeutics earnings · how Allogene Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.